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Abstract 
One of the features of the ICER stakeholder involvement in the development of ICER evidence reports is the ability for public comment. 
Unfortunately, and this may just a miscommunication, the replies from ICER to public comments frequently miss the point or fa il to 
provide backup for their claims. The purpose of this commentary is to review ICER’s responses to public comments by the author on the 
just released final evidence report on cystic fibrosis. The message is quite simple: the ICER value assessment framework lacks credibility. 
It fails to meet the standards of normal science. This is seen in ICERs apparent ignorance or rejection of the axioms of fundamental 
measurement which point quite clearly to the mathematical impossibility of creating QALYs from generic multiattribute utility scores. 
The ICER report also fails standards by creating a model from prior assumptions; there is no logical basis for constructing a value 
assessment claim. Either ICER should withdraw its value claims or admit the dubious basis on which the model is built, as a duty to its 
readership. 
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Introduction 
The construction of assumption driven imaginary worlds to 
support incremental cost-per-QALY claims for pricing and 
access recommendations is the hallmark of the Institute for 
Clinical and Economic Review’s (ICER) business model. ICER has 
issued two evidence reports on cystic fibrosis. The first report, 
a final evidence report was released in 2018; the second report, 
a draft evidence report, on 20 February 2020 1 2. Following the 
draft evidence report release a commentary was published in 
INNOVATIONS In Pharmacy pointing to the manifest 
shortcomings in the ICER value assessment framework 3. 
Following the release of the draft evidence report, the 
opportunity presented itself to try and gauge ICER;’s beliefs in 
respect of fundamental measurement and the construction of 
imaginary cost-per-incremental QALY worlds. A series of 
questions were presented with a response to each question 
posted to the ICER website. 
 
The purpose of this commentary is to consider and respond to 
the replies received ICER. This is a useful exercise because it is 
quite clear from these responses that ICER either does not 
appreciate or possibly chooses not to understand the axioms of 
fundamental measurement. This is a critical shortcoming 
because it points to ICER not understanding that the utility 
scales that are generated by   multiattribute instruments  such  
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as the EQ-5D-3L, EQ-5D-5L and HUIMk3, are only able to 
generate ordinal or manifest scores. The utilities cannot be 
used to create QALYs because a manifest score cannot support 
the   fundamental   four arithmetic   operations   of    addition,  
subtraction, multiplication and division. Absent multiplication a 
QALY is an impossible construct. Formulary submissions that 
rely on QALYs should, therefore, be rejected out of hand. It is 
not a question of approximate information but of ‘information’ 
that is pure fantasy 4. 
 
The impossibility of creating QALYs was made clear in the 
covering letter accompanying the list of questions posed for 
ICER response 5:  
 
 The EQ-5D has only ordinal properties, it is a 
manifest scale, and should not be used to 
construct QALYs. If your staff are unaware of 
measurement properties for instruments in the 
social sciences for non-physical attributes, I 
would be pleased to explain this to them. 
Unfortunately, apart from the lack of scientific 
merit in constructing lifetime imaginary models, 
the misapplication of the EQ-5D-3L utilities 
means that your reference case model collapses. 
 
As a first step, however, the scene needs to be set with a brief 
review of the axioms of fundamental measurement. 
 
Fundamental Measurement 
In the physical sciences, the creation of instruments with the 
appropriate measurement properties is central to hypothesis 
testing and the discovery of new facts. The same standards 
should apply to the social sciences, hence the importance of 
conjoint simultaneous measurement and Rasch Measurement 
Theory (RMT) in instrument development 6. For our purposes, 
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we can focus on the axioms as they relate to basic arithmetic 
operations.  
 
Our starting point must be to point out that multiattribute 
utility scales are ordinal or manifest scores. This has been 
recognized for the past 30 years. This may be considered 
heresy, but the key to unraveling the technology assessment 
belief system is to make clear that multiattribute utility scales 
have neither interval nor ratio properties. Analysts may believe 
they have; they may also believe in fairies at the bottom of the 
garden or even the Easter Bunny. But that is irrelevant. 
 
Four main types of measurement scale are recognized: 
nominal, ordinal, interval and ratio. Each satisfies one or more 
of the properties of: (i) identity, where each value has a unique 
meaning; (ii) magnitude, where each value has an ordered 
relationship to other values; (iii) interval, where scale units are 
equal to one another; and (iv) ratio, where there is  a ‘true zero’ 
below which no value exists. Nominal scales are purely 
descriptive and have no inherent value in terms of magnitude. 
Ordinal scales have both identity and magnitude in an ordered 
relation but the unknown distances between the ranks means 
the scale is capable only of generating medians and modes. The 
interval scale has identity, magnitude and equal intervals. It 
supports mathematical operations of addition and subtraction. 
A ratio scale satisfies all properties, supporting the additional 
mathematical operations of multiplication and division.  
 
The case for multiattribute utility scales failing the standards for 
interval, let alone ratio measurement is that they rely on 
preference weights attached to ordinal response levels for the 
symptoms captured by the instrument. The EQ-5D-3L, for 
example is constructed from five symptom levels each 
characterized by three response levels (no problem, some 
problems and extreme problems). These responses can be 
ranked but we have no idea of the difference between them. 
You can attach community preferences or weights to the 
various response levels, add these and create a single utility, 
but you will still have an ordinal or manifest score; a scale that 
fails the axiom of invariance of comparisons. Just because you 
set an algorithm that is supposed to generate utilities on a dead 
= 0 and 1 = perfect health does not mean that the 0 is a true 
zero or that the space between 0 and 1 has interval properties. 
Instruments have to be designed to meet measurement 
standards; not assumed to have them ex post facto.  
 
The ratio scale has a true zero where the value of a variable has 
no value at all below zero. Because of this it can support all 
arithmetic operations. A zero point is an essential 
characteristic. To measure a ratio between any two variables is 
impossible in the absence of zero, the reference point for all 
calculations. In the absence of a zero you cannot say that 
George weighs twice as much as Donald (300 lbs vs 150 lbs: a 
ratio of 2).   We need a zero point to determine the distance 
from zero to support multiplication and division, as well as 
interval properties to support addition and subtraction. These 
attributes are lacking in the multiattribute utility systems as 
well as the majority of patient reported outcomes   (PRO) 
instruments. This includes, for example the most frequently 
used instrument in cystic fibrosis, the Cystic Fibrosis 
Questionnaire (CFQ) 7. It fails the standards for fundamental 
measurement; it is an ordinal measure. This applies to all 
versions of the CFQ for adults, pediatrics and caregivers, 
together with the various subscales. The CFQ may meet the 
standards for classical test theory; but fails when assessed 
against the required standards exemplified by Rasch 
measurement theory. 
 
It is important to note that over the past 25 years considerable 
attention has been given to the problem of negative utilities 
(from both time trade off [TTO] and the EQ-5D -3L) as well as to 
the possible transformation from the ordinal response or 
ranked manifest scores of the EQ-5D to cardinal or interval 
measures 8. So far, these efforts have failed to produce any 
concrete results. This is not surprising. We have techniques for 
translating ordinal to interval scores but this requires the 
application of Rasch Measurement Theory; the creation of ratio 
scales is more complex. The result, therefore, is that groups 
such as ICER continue to apply the EQ-5D utilities as if they were 
on a ratio scale (to include interval properties). Unfortunately, 
the audience for ICER may not share these insights. ICER may 
believe; on the other hand ICER may be well aware of the 
‘assumption’, knowing it is false 9.  
 
Questions to ICER 
A total of 20 questions, with a covering letter detailing key 
references, were submitted to ICER for their consideration and 
response. Fourteen were selected to provide comments on the 
ICER response. These follow: 
 
1. Questions to ICER: EQ-5D Absence of Ratio Property 
 
Question: It appears that many people building simulated 
imaginary lifetime models (e.g., ICER Value Assessment 
Framework) believe that it is appropriate to consider the EQ-
5D-3L (used in the cystic fibrosis model) as having ratio 
properties (i.e., a true zero). As this is incorrect, would you 
explain why you persist? If you are unsure of the meaning of 
measurement scales, a full description of their mathematical 
properties is included in file:  
 
///C:/Users/Paul/Downloads/Working%20Paper%20No.% 
205%20March%202020.pdf 
 
You might also refer to the Bond and Cox reference on Rasch 
measurement theory. 
 
ICER Response: We (and most health economists) have the 
understanding that the EQ-5D (and other multi-attribute utility 
instruments) do have ratio properties. The EQ-5D value sets are 
based on time trade-off assessments (which are interval level) 
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Comment: If most health economists do, which I doubt, then 
they are deluding themselves. The EQ-5D cannot have ratio 
properties as it lacks a true zero; the EQ-5D-3L algorithm 
generates negative utilities (lowest is -0.59) with an artificial 
starting point of unity. Given the absence of ratio properties the 
EQ-5D utility cannot be used to create QALYs as this requires 
multiplication (i.e., a true zero with no negative values).  Can 
ICER demonstrate that the time-trade-off value sets have 
interval properties (i.e., invariance of comparisons?). Certainly, 
the time trade off (TTO) creates a raw score but this can take 
negative values for fates worse than death (ratios of time 
spent); but this does not mean that scale has interval properties 
10. The TTO also has a slight problem in dividing by zero for 
preferred immediate death. Are you familiar with the lead-
time/lag-time literature on transforming TTO scores to avoid 
states worse than death? The TTO does not have either ratio or 
interval properties. Think: relative differences rather than raw 
time trade off scores! In any event that is irrelevant as the EQ-
5D algorithm also generates negative utilities. You might 
consider reading the references provided. I recommend the 
Bond and Cox which points to the inherent difficulties of 
creating a ratio scale together with the Rasch transformation of 
raw scores to an interval scale.   
 
2. Questions to ICER: Absence of Interval Properties 
 
Question:  It has been recognized for almost 20 years that the 
EQ-5D-3L utilities are an ordinal manifest score as the basis for 
creating their utilities are responses on an ordinal scale for five 
symptoms with three response levels for each symptom. If ICER 
believes this is not the case, in continuing to use the EQ5D-3L, 
could ICER explain why they take this view? If you are unaware 
of this literature please consider the references below by 
Grimby et al, Tennant et al, McKenna et al (2 papers) 11 12 13 14. 
 
ICER Response: We (and most health economists) have the 
understanding that the EQ-5D (and other multi-attribute utility 
instruments) do have interval-level properties. The EQ-5D value 
sets are based on time trade-off assessments (which are interval 
level), with preference weights assigned to different attributes. 
We fail to see why this should be considered as an ordinal 
(ranked) scale. 
 
Comment: Again, read the references provided. We have 
known for over 20 years that the EQ-5D does not have interval 
properties. It was not designed to have interval properties 
(because no one asked the question). Note that the five 
symptoms that characterize the EQ-5D rest on ordinal scales for 
symptom response (i.e., we don’t know the difference between 
response levels: no problem, some problems, extreme 
problems). If you attach weights or just integers to ordinal 
responses you end up with an ordinal scale (e.g., attempting to 
add up Likert scale values across question items; see Bond and 
Cox Ch. 6). Even if the EQ-5D had interval properties you could 
not generate QALYs because an interval scale only supports 
addition and subtraction, not multiplication. For this you need 
a ratio scale, which you do not have. You can create an interval 
scale from ordinal ranks; but that is not what occurs with the 
EQ-5D. Again read Bond and Cox (pp30-31), noting the 
contributions of Thurstone in the 1920s 6. The purpose of RMT 
is to translate ordinal responses to an interval scale. Again read 
the references. 
 
3. Questions to ICER: Invariance of Comparisons  
 
Question: If ICER rejects the notion of the EQ-5D-3L as an 
ordinal manifest score, could ICER demonstrate that, if we 
consider the interval measurement scale, that the EQ-5D-3L for 
the cystic fibrosis population has invariance of comparisons? 
Could ICER discuss this in the context of floor and ceiling 
effects? Is the utility difference between 0.4 and 0.45 equal to 
that between 0.8 and 0.85? 
 
ICER Response: The EQ-5D multi-attribute utility function is 
designed so that a utility difference of 0.05 is considered 
equivalent regardless of the starting point. 
 
Comment: Really! If it was designed to have an interval scale, 
invariance of comparisons, then it has failed miserably. What 
does ‘consideration’ mean? It may have but may not? The lack 
of interval scaling properties has been remarked for the last 20 
years (floor effects, ceiling effects, bunching at extreme values, 
negative utilities). Does going from 0 to 0.05 the same as going 
from -0.4 to -0.45? What does this mean? Can ICER 
demonstrate that the EQ-5D-3L scale has this property? If it was 
designed to have interval scaling properties then it must have 
been designed to have negative interval scaling properties! 
How do you go from five symptom levels with ordinal 
properties to a utility scale with interval properties where the 
algorithm creates negative utilities? Again, in any event, you 
need a ratio scale not an interval scale to create QALYs. 
 
4. Questions to ICER: The Dead State  
 
Question: If ICER accepts that the EQ-5D-3L has interval 
properties and moves to ratio properties, can ICER demonstrate 
that the EQ-5D-3L has a ‘true zero’? How would ICER reconcile 
this to the fact that with the EQ-5D-3L preference algorithm the 
lowest utility value allowed is -0.59? Would ICER agree that this 
invalidates the notion of a ‘true zero’? 
 
ICER Response: ICER believes that the dead state represents a 
natural zero point on a scale of health-related quality of life. 
Negative utility values on the EQ-5D scale represent states 
considered worse than dead. 
 
Comment: Clutching at straws here! ICER might believe this; 
ICER might also believe in fairies at the bottom of the garden. 
Belief is irrelevant. What does ‘natural zero’ mean? Is this a 
weight of zero on a weigh scale (a true zero) as you cannot have 
a negative weight? It is gratifying that ICER acknowledges the 
existence of negative utilities (i.e. If you admit it then the EQ-
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5D-3L cannot be a ratio scale) but perhaps ICER does believe 
this? Are negative utility values the equivalent of negative 
weights? It is not a true zero; it is just an artifact of the scoring 
algorithm. You should possibly adjust your preference 
weighting to make sure that there a no negative utilities but at 
least one health state that yields  a “0” dead state (or possibly 
slightly higher to show you are at death’s door) Again, you 
should really read the references. However, if ICER truly and 
deeply believes the dead state to be a true zero, then so be it. 
But ICER should make its audience aware of its firmly held 
belief. 
 
5. Questions to ICER: Please see above 
 
Question: If ICER cannot demonstrate that the EQ-5D-3L has 
ratio properties (let alone latent measurement properties) how 
can ICER persevere with its value assessment framework and 
recommendations for pricing and affordability? If the EQ-5D-3L 
algorithm allows for negative utilities (which it does) then this 
is conclusive that there is no ‘true zero’ and the notion of a 
QALY collapses because multiplication is disallowed.  
 
ICER Response: We disagree. Please see the responses above. 
 
Comment: Please see above is an ICER stock response. If ICER 
disagrees then a stronger case should be put forward for the 
belief that the axioms of fundamental measurement do not 
apply in their lifetime cost-per-QALY imaginary worlds. It is not 
a question of disagreement; it is a question of the axioms of 
fundamental measurement formulated by Stevens in 1946 15. 
ICER needs to start from recognition of the importance of 
fundamental measurement and not by unsupported belief in 
the value, if any, of the EQ-5D or similar utilities as the basis for 
QALY claims. ICER has yet to demonstrate the EQ-5D-3L or 5L 
have interval or even ratio properties; let alone the other 
multiattribute generic measures. Of course, as the EQ-5D-3L 
yields negative utilities, that means that ICER is prepared to 
recognize negative QALYs. Perhaps ICER can tell its audience 
how negative utilities are accommodated in its value 
framework? Can the modeled lifetime health path 
accommodate patients moving between negative and positive 
QALYs? Are lifetime QALYs the aggregate of the negative and 
positive time states? What happens when a hypothetical 
patient group only experiences negative QALYs? Can we have 
cost per negative QALY? 
 
6. Questions to ICER: An Abundance of Assumptions  
 
Question: Is ICER prepared to argue that while the EQ-5D-3L 
fails the standards of fundamental measurement, this is 
immaterial in its construction of imaginary value assessment 
frameworks as they are only driven by assumption anyway? 
 
ICER Response: As stated above, we do not accept the premise 
of this question. 
Comment: What premise? That the ICER value assessment 
framework is simply a set of (one among many) assumptions? 
If ICER staff had reviewed the references provided, they might 
have appreciated the fact that that you cannot assume that 
what has been observed in the past can be used to support 
assumptions about the future. This belief fails to recognize 
Hume’s problem of induction. How do we justify the prediction 
of instances of which we have no experience resemble those of 
which we have had  experience? 16  Or. as Magee puts it: The 
whole of our science assumes the regularity of nature – assumes 
the future will be like the past in all those respects in which 
natural laws are taken to operate – yet there is no way in which 
this assumption can be secured. It cannot be established by 
observation, since we cannot observe future events. And it 
cannot be secured by logical argument, since from the fact that 
all past futures have resembled past pasts it does not follow that 
all future futures will resemble future pasts 17. You cannot 
assume it will hold in the future; even if shrouded by scenarios 
and sensitivity tests. So why create imaginary worlds? Who will 
believe you? Hugo awards for science fiction? 
 
7. Questions to ICER: Descriptive and Predictive Models 
 
Question: Is the reference case imaginary lifetime model 
intended to generate credible, evaluable and replicable claims 
for cost-effectiveness? If not, why not? 
 
ICER Response; Descriptive and predictive models are a 
mainstay of economic analyses, as well as most other scientific 
disciplines. We use transparent models that follow standard 
practices and are subjected to multiple scenario and sensitivity 
analyses. 
 
Comment: Again, ICER fudges a response. The terms are not 
defined. Certainly there is a role for descriptive models to 
define a structure and possible relationships as a step to 
formulating hypotheses. Predictive modeling raises the more 
pertinent question of whether ICER believes in testing 
hypotheses? The ICER models are certainly not intended to 
meet the standards of normal science: to generate credible, 
evaluable and replicable claims. ICER has instead embraced the 
creation of predicted 30 year imaginary claims which fail to 
meet the predictive standards of normal science. They are 
pseudoscience, sharing the Dover courtroom with intelligent 
design 18. If the model is a non-evaluable fantasy construct then 
no amount of scenario analysis and probabilistic claims will save 
it. Of course you can claim transparency in your choice of one 
model structure and set of assumptions among many other 
possible modeled worlds; this is your prerogative.  
 
8. Questions to ICER: My fantasy model is better than 
your fantasy model  
 
Question: How much credibility should be attached to the ICER 
model when it is only one of many that could create imaginary 
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claims in cystic fibrosis for the products assessed? What sets 
the ICER model apart from others? 
 
ICER Response: We produce detailed reports describing the 
model's structure, assumptions, and inputs so that readers may 
judge the credibility of the model. At the draft report stage, we 
also share the actual model with relevant manufacturers for 
feedback and critique (the manufacturer of the treatments in 
this review declined to participate). In addition, we compare the 
model to prior published models in the same therapeutic area 
 
Comment: So what? It still comes down to a contest ‘my model 
is better than your model’. My model can best represent the 
next 30 years of cystic fibrosis treatments and responses in 
target populations! Why? Why bother? You can’t validate your 
model in terms of other models which are also fantasy 
constructs. The argument is somewhat circular with each model 
building group validating their model in terms of other models. 
Of course, if ICER addressed the question of hypothesis testing 
of claims (impossible) this may give a more useful base for 
comparing modeled claims. Vertex, the cystic fibrosis product 
manufacturer has, wisely, refused to participate in this value 
assessment modeling exercise.   
 
9. Questions to ICER: No Evidence?  
 
Question: In the 2018 ISPOR task force report on health 
economics approaches to value assessment determined that 
economic evaluations are intended, not to test hypotheses, but 
to inform decision makers of the approximate value of 
interventions in terms of imaginary incremental cost-per-QALYs 
gained 19. Does ICER subscribe to this view? How approximate 
is the modeled information in cystic fibrosis? 
 
ICER Response: ICER's value framework recognizes that 
decisions need to be made using evidence available at the time, 
no matter how approximate or uncertain. Our reports discuss in 
detail the variance and uncertainty around the available 
evidence for the clinical effectiveness of treatments. Our 
economic analyses explore uncertainty via scenario and 
sensitivity analyses, including probabilistic sensitivity analyses 
over plausible ranges of values. 
 
Comment: Presumably, in the complete absence of 
‘information’ ICER will still build a lifetime reference model and 
create recommendations, modeling 30 years into the future? Is 
there a cutoff for determining whether or not there is sufficient 
information to justify assumptions and create an imaginary 
world? Of course, we can fall back on that catch-all term 
‘uncertainty’; but the focus is on claims that are neither credible 
nor evaluable. Lack of evidence is not a problem; with an 
abundance of assumptions capturing the 30 year value 
assessment, a few more assumptions (true, sort of true, false) 
will hardly make any difference. How do you gauge ‘plausibility’ 
of an assumption when you are venturing 30 years into the 
future? Is there a criterion for ‘plausibility”? What about entry 
of new products in the disease area? Is it ‘sort of realistic’ 
according to your model building team? If nothing changes this 
is what we think will happen? The ICER claims are still safe from 
any presumptuous attempt to match these to observations – 
which are in the future anyway. The induction problem, if ICER 
has even recognized its import, can be quietly ignored. 
 
10. Questions to ICER: Providing approximate 
Information or ‘the truth is out there’ 
 
Question: In respect of 12 (8) (above) how would ICER define 
the ‘approximate value’ of its cystic fibrosis modeling for 
incremental cost-per-QALY gains? How is this to be 
distinguished from ‘approximate disinformation’? 
 
ICER Response: See response above (actually not very helpful) 
 
Comment: it is not clear how ICER reconciles its commitment to 
modeling for approximate information to its professed 
commitment to predictive modelling. Perhaps the predictions 
are no meant to be evaluated empirically (yet 30 years out); a 
class of imaginary predictions If so, it is clear that ICER is 
committed to pseudoscience with the  endorsement of the 
ISPOR commitment to generating approximate information. 
But this is odd; approximate information in respect of what? An 
unknown 30 year ‘the truth is out there’ model where the 
reference point to define ‘approximate’ is non-existent; a truth 
constructed from impossible QALYs yielding an impossible 
incremental cost-per-QALY ‘master’ scenario? Would other 
‘approximate information’ models have their own ‘the truth is 
out there’ unknown and unknowable reference point for their 
alternative universe? 
 
11. Questions to ICER: Latent Unidimensionality 
 
Question: Could ICER detail whether or not the EQ-5D-3L, as a 
health related quality of life measure, has a latent 
unidimensional construct? If not, how are we to characterize 
the ‘construct’ (if any) that supports this instrument? 
 
ICER Response: As above, please see the literature on multi-
attribute utility theory (again, not very helpful). 
 
Comment: Another fudge. It is not clear as to whether or not 
ICER understood the question. A central tenet of measurement 
theory is that only one attribute should be captured by an 
instrument (e.g., temperature, needs fulfillment). The 
multiattribute generic instruments are, frankly, a dog’s 
breakfast of different attributes or latent constructs. This is 
unfortunate, because the ability to capture change is 
attenuated (see Bond and Cox). The solution, long recognized 
in the physical science and in education (to a lesser extent 
psychology) is to capture one attribute at a time. There is no 
latent construct for the EQ-5D; it is simply a collection of 
clinician determined symptoms (pain, mobility, depression, 
etc.) each of which should be a measure in its own right. The 
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catch-all label health related quality of life (HRQoL) is then 
attached. It is not clear what attributes are being captured and 
how we should interpret these aggregate responses as an 
ordinal manifest score. What is driving a change in 
(hypothetical) utility score? Is it relevant to that disease state? 
Is it relevant to patients who would be in a more defensible 
position to respond on their own? 
 
12. Questions to ICER: The Patient Voice 
 
Question: It has been recognized since the 1960s (and in health 
technology assessment since the 1990s) that if we are to 
capture the patient voice in therapy assessments, we require a 
needs based QoL instrument to capture therapy impacts with 
interval measurement properties. Why has ICER continued to 
apply generic measures of HRQoL defended by what many see 
as a bogus population perspective argument? Could ICER 
provide their case for non-patient centric HRQoL measures? 
 
ICER Response: The quality-of-life weights we used in 
calculating QALYs were derived from EQ-5D responses from CF 
patients in a prior published study. Appropriate data on HRQoL 
from the relevant clinical trials were not available. We 
encourage manufacturers and researchers to include disease-
specific and generic measures of HRQoL/utility in future studies. 
 
Comment: A walk around the question. ICER appears to put 
generic HRQoL claims ahead of patient centric disease specific 
claims. Presumably this is to maintain the ‘integrity’ of their 
imaginary value assessment framework. ICER will never 
countenance a shift to disease specific modelling of evaluable 
quality of life claims which meet the interval standards of 
fundamental measurement because it would destroy their 
value assessment framework which relies on multiattribute 
generic cost per QALY calculations. Yet, such instruments exist 
and meet the standards of RMT 20. Again, ICER avoids the 
question (and fails to read references) 
 
13. Questions to ICER: The ICER methodology is not 
flawed (?).  
 
Question: In the ICER modeled case for cystic fibrosis, there is a 
clear case, based on fundamental measurement, to reject the 
modeled cost-per-QALY claims? Given ICERs persistence with 
this flawed methodology, why should we take these threshold 
cost-per-QALY claims and pricing recommendations seriously? 
How does ICER defend these recommendations? 
 
ICER Response:  As outlined in the responses above, we disagree 
with the premise that the methodology is flawed. 
 
Comment: I think ICER’s responses to the questions raised in 
the public comment are sufficient to respond to this assertion. 
After all, ICER is apparently the self-appointed arbiter of 
technology assessment for new products in the US. As to 
‘flawed’, ICER could hardly admit otherwise. If it did then it 
would have to withdraw all previous evidence reports and 
recommendations for pricing a product access. 
 
14. Questions to ICER: Any serious evaluable claims? 
 
Question: Apart from the fatal measurement assumptions, ICER 
asks us to believe that is possible (even with the problematic 
EQ-5D-3L manifest score) that the claims for a range of 
outcome measures should be taken seriously? Is there any 
intent on ICER’s behalf that these claims should meet the 
standards of normal science for credibility, evaluation and 
replication? 
 
ICER Response: As mentioned above, descriptive and predictive 
models such as this are a mainstay of economic analyses, as well 
as many other scientific disciplines. 
 
Comment: Another fudged response. We are probably going 
around in circles. Creating imaginary worlds which lack any 
pretense to meet the standards of normal science is ridiculous. 
As a professional economist with over 40 years of experience it 
was not until I encountered the world of health technology 
assessment that these imaginary constructs appeared. Yes, 
creating imaginary ICER-type value assessment frameworks has 
been a mainstay of formulary admissions in countries with 
single payer health systems. There is no reason we should 
emulate them. But imaginary worlds to support non-evaluable 
claims that stretch 30 years in the future are not an accepted 
feature of mainstream economics. What ICER can’t see is that 
it is in an analytical dead end. ICER may talk about predictive 
models but has no interest in developing them. Instead it relies 
on a bizarre interpretation of the axioms of fundamental 
measurement to support impossible QALYs in imaginary 
worlds.  
 
Next Steps 
Assuming there are any; after all, the view is that the ICER value 
assessment framework is an analytical dead-end. This is 
reinforced by ICER’s response to questions which give little 
support to those who would defend ICER on its knowledge of 
fundamental measurement. On its own, the belief, strongly 
held that all generic instruments have ratio (encompassing 
interval) properties should be a sufficient red flag for discarding 
ICER models and their recommendations for price discounts 
and access. It was pointed out some 30 years ago that it was 
time to reject misinference from ordinal scales and their 
misapplication in clinical decision making 21.  
But ICER will persevere! It will attempt to shrug off the 
fundamental measurement qualifications; it will continue to 
create generic QALYS and model claims for incremental cost per 
QALY thresholds that fail the standards of normal science. ICER 
is publishing pseudoscience. Unfortunately, if the belief is that 
truth is consensus and evidence is constructed not discovered, 
then there is a surprisingly large audience 22.  
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A Duty to Inform 
ICER has a duty to inform its readership that it is employing a 
value assessment framework that, to put it in the best possible 
light, admits of alternative views. The ICER media releases 
should at least caution the reader that the construct does not 
meet the standards of normal science; it fails the demarcation 
test. It should be seen as pseudoscience in that it lacks claims 
that are credible evaluable and replicable. Obviously, ICER’s 
assumptions are largely evidence based; from prior studies 
reported in the literature. There is no logical basis for assuming 
any of the assumptions will hold into the future. The media and 
the ICER readership, including those manufacturers supporting 
ICER, should be advised that there are also a number of critical 
assumptions that do not stand up to scrutiny. These relate to 
the axioms of fundamental measure and their properties, or 
lack of, in utility scales. If ICER believes that the EQ-5D-3L has 
ratio properties, this position needs to be defended; if ICER 
recognizes that the EQ-5D-3L lacks ratio properties but, in 
defiance of the evidence, is prepared to make this assumption 
to defend the construction of QALYs, then this should be stated 
clearly.. 
Failure to inform its readership, including those formulary 
committees and other health decision makers who take ICER’s 
claims at face value, need to be made aware of the various 
criticisms directed to the ICER value assessment framework. 
The claims are imaginary. The argument that other analysts 
employ the same paradigm is no defense. If ICER subscribes to 
the belief in providing ‘approximate’ imaginary information, 
then this should be made clear. Is it approximate yet, in some 
sense, relevant? ICER needs to make its position clear.   
It is one approach to act on belief  (rather than logic and 
evidence), yet another to put to one side critical appraisals of 
utility scores and QALYs when the model builders are aware of 
the lack of interval and ratio properties in utility scores, yet 
apparently choose to ignore them. Perhaps ICER should 
gracefully withdraw, yielding the ground to normal science. As 
Tennant et al made clear some 16 years ago: As long as 
primitive counts and raw scores are routinely mistaken for 
measures by our colleagues in social, educational and health 
research, there is no hope of their professional activities ever 
developing into a reliable or useful science 11.  
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